Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction

Ersilia M DeFilippis, Avinainder Singh, Sanjay Divakaran, Ankur Gupta, Bradley L Collins, David Biery, Arman Qamar, Amber Fatima, Mattheus Ramsis, Daniel Pipilas, Roxanna Rajabi, Monica Eng, Jon Hainer, Josh Klein, James L Januzzi, Khurram Nasir, Marcelo F Di Carli, Deepak L Bhatt, Ron Blankstein, Ersilia M DeFilippis, Avinainder Singh, Sanjay Divakaran, Ankur Gupta, Bradley L Collins, David Biery, Arman Qamar, Amber Fatima, Mattheus Ramsis, Daniel Pipilas, Roxanna Rajabi, Monica Eng, Jon Hainer, Josh Klein, James L Januzzi, Khurram Nasir, Marcelo F Di Carli, Deepak L Bhatt, Ron Blankstein

Abstract

Background: Substance abuse is increasingly prevalent among young adults, but data on cardiovascular outcomes remain limited.

Objectives: The objectives of this study were to assess the prevalence of cocaine and marijuana use in adults with their first myocardial infarction (MI) at ≤50 years and to determine its association with long-term outcomes.

Methods: The study retrospectively analyzed records of patients presenting with a type 1 MI at ≤50 years at 2 academic hospitals from 2000 to 2016. Substance abuse was determined by review of records for either patient-reported substance abuse during the week before MI or substance detection on toxicology screen. Vital status was identified by the Social Security Administration's Death Master File. Cause of death was adjudicated using electronic health records and death certificates. Cox modeling was performed for survival free from all-cause and cardiovascular death.

Results: A total of 2,097 patients had type 1 MI (mean age 44.0 ± 5.1 years, 19.3% female, 73% white), with median follow-up of 11.2 years (interquartile range: 7.3 to 14.2 years). Use of cocaine and/or marijuana was present in 224 (10.7%) patients; cocaine in 99 (4.7%) patients, and marijuana in 125 (6.0%). Individuals with substance use had significantly lower rates of diabetes (14.7% vs. 20.4%; p = 0.05) and hyperlipidemia (45.7% vs. 60.8%; p < 0.001), but they were significantly more likely to use tobacco (70.3% vs. 49.1%; p < 0.001). The use of cocaine and/or marijuana was associated with significantly higher cardiovascular mortality (hazard ratio: 2.22; 95% confidence interval: 1.27 to 3.70; p = 0.005) and all-cause mortality (hazard ratio: 1.99; 95% confidence interval: 1.35 to 2.97; p = 0.001) after adjusting for baseline covariates.

Conclusions: Cocaine and/or marijuana use is present in 10% of patients with an MI at age ≤50 years and is associated with worse all-cause and cardiovascular mortality. These findings reinforce current recommendations for substance use screening among young adults with an MI, and they highlight the need for counseling to prevent future adverse events.

Keywords: cocaine; marijuana; myocardial infarction; substance abuse; young adults.

Figures

FIGURE 1. Trends in Substance Use Over… — **FIGURE 1. Trends in Substance Use Over Time**
Trends in **(A)** cocaine and **(B)** marijuana use over the course of the study period, 2000 to 2016. The **thick dashed line** represents a fitted regression Line and the **thinner dashed lines** are confidence intervals. MI = myocardial infarction. **Triangles** represent the percentage of patients with MI for the particular year who used cocaine. **Asterisks** represent the percentage of patients with MI for the particular year who used marijuana.

FIGURE 2. All-Cause Mortality and Cardiovascular Mortality… — **FIGURE 2. All-Cause Mortality and Cardiovascular Mortality in Patients With Substance Abuse**
Kaplan-Meier curves of **(A)** all-cause mortality and **(B)** cardiovascular mortality in patients with substance abuse compared with patients without substance abuse. HR = hazard ratio.

FIGURE 3. Annual Incidence Rates for All-Cause… — **FIGURE 3. Annual Incidence Rates for All-Cause Death and Cardiovascular Death**
Observed annual death and cardiovascular death rates are shown by drug of abuse in 100 person-years.

FIGURE 4. All-Cause Mortality and Cardiovascular Mortality… — **FIGURE 4. All-Cause Mortality and Cardiovascular Mortality Stratified by Use of Cocaine or Marijuana**
Kaplan-Meier curves of (A) all-cause mortality and (B) cardiovascular mortality by drug of abuse.

FIGURE 5. Adjusted Cardiovascular Mortality and All-Cause… — **FIGURE 5. Adjusted Cardiovascular Mortality and All-Cause Death**
Forest plots are shown for adjusted models of all-cause and cardiovascular (CV) death. AU-cause death was adjusted for age, sex, presence of diabetes, hypertension, peripheral vascular disease, smoking, high-density lipoprotein cholesterol, triglycerides, revascularization, creatinine, medications at discharge, and length of stay. CV death was adjusted for age, presence of diabetes, hypertension, peripheral vascular disease, smoking, high-density lipoprotein cholesterol, creatinine, medications at discharge, and length of stay. Adj. HR = adjusted hazard ratio; CI = confidence interval.

CENTRAL ILLUSTRATION. Cocaine and Marijuana Use in… — **CENTRAL ILLUSTRATION. Cocaine and Marijuana Use in Young Patients With Myocardial Infarction**
We found that in our young patients with myocardial infarction (MI), approximately 10% were using either cocaine or marijuana. Cocaine use increases myocardial oxygen demand, decreases oxygen supply, and accelerates atherosclerosis and can create a prothrombotic state. Marijuana use leads to the generation of reactive oxygen species, decreases myocardial contractility, and leads to neointimal proliferation of vascular smooth muscle cells. Substance abuse was associated with increased all-cause mortality and cardiovascular mortality.

References

1. National Institute for Drug Abuse. Nationwide Trends: Drug Facts. 2015. Available at: . Accessed April 12, 2018.
1. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-Elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64: e139–228.
1. Moliterno DJ, Willard JE, Lange RA, et al. Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both. N Engl J Med 1994; 330:454–9.
1. Ravi D, Ghasemiesfe M, Korenstein D, Cascino T, Keyhani S. Associations between marijuana use and cardiovascular risk factors and outcomes: a systematic review. Ann Intern Med 2018;168:187–94.
1. Frost L, Mostofsky E, Rosenbloom JI, Mukamal KJ, Mittleman MA. Marijuana use and long-term mortality among survivors of acute myocardial infarction. Am Heart J 2013;165:170–5.
1. Pacher P, Steffens S, Haskó G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol 2018;15:151–66.
1. Renard D, Taieb G, Gras-Combe G, Labauge P. Cannabis-related myocardial infarction and cardioembolic stroke. J Stroke Cerebrovasc Dis 2012;21:82–3.
1. Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol 2014;113: 187–90.
1. Singh A, Collins B, Qamar A, et al. Study of young patients with myocardial infarction: design and rationale of the YOUNG-MI Registry. Clin Cardiol 2017;40:955–61.
1. Thygesen K, Alpert JS, Jaffe AS, et al. Third Universal Definition of Myocardial Infarction. J Am Coll Cardiol 2012;60:1581–98.
1. Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol 2015;66:403–69.
1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.
1. Cole SR, Hernán MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 2004;75:45–9.
1. Gupta N, Washam JB, Mountantonakis SE, et al. Characteristics, management, and outcomes of cocaine-positive patients with acute coronary syndrome (from the National Cardiovascular Data Registry). Am J Cardiol 2014;113:749–56.
1. Shitole SG, Kayo N, Srinivas V, et al. Clinical profile, acute care, and middle-term outcomes of cocaine-associated ST-segment elevation myocardial infarction in an inner-city community. Am J Cardiol 2016;117:1224–30.
1. Rangel C, Shu RG, Lazar LD, Vittinghoff E, Hsue PY, Marcus GM. Beta-blockers for chest pain associated with recent cocaine use. Arch Intern Med 2010;170:874–9.
1. Dattilo PB, Hailpern SM, Fearon K, Sohal D, Nordin C. Beta-blockers are associated with reduced risk of myocardial infarction after cocaine use. Ann Emerg Med 2008;51:117–25.
1. Ibrahim M, Maselli DJ, Hasan R, Hamilton A. Safety of b-blockers in the acute management of cocaine-associated chest pain. Am J Emerg Med 2013;31:613–6.
1. Fanari Z, Kennedy KK, Lim MJ, Laddu AA, Stolker JM. Comparison of in-hospital outcomes for beta-blocker use versus non-beta blocker use in patients presenting with cocaine-associated chest pain. Am J Cardiol 2014;113: 1802–6.
1. Sidney S Cardiovascular consequences of marijuana use. J Clin Pharmacol 2002;42: 64S–70S.

Source: PubMed

Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction

Abstract

Figures

References

Sponsors and Collaborators

Medical Conditions

Drug Interventions